EP0804933B1 - Lagerstabile Fibrinogen-Präparate - Google Patents
Lagerstabile Fibrinogen-Präparate Download PDFInfo
- Publication number
- EP0804933B1 EP0804933B1 EP97106568A EP97106568A EP0804933B1 EP 0804933 B1 EP0804933 B1 EP 0804933B1 EP 97106568 A EP97106568 A EP 97106568A EP 97106568 A EP97106568 A EP 97106568A EP 0804933 B1 EP0804933 B1 EP 0804933B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- fibrinogen
- vitamin
- preparation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to storage-stable fibrinogen preparations for Preparation of concentrated fibrinogen solutions for Use as a tissue adhesive or for the preparation of Fibrinogen solutions for other applications, e.g. for Infusion purposes.
- the storage-stable fibrinogen preparations can either be in lyophilized form or as frozen (especially highly concentrated) fibrinogen solutions are present and have the advantage of being easier and faster than before known ready-to-use preparations Reconstituted fibrinogen or tissue adhesive solutions or can be liquefied.
- the invention also includes those from the Fibrinogen or Tissue adhesive solutions.
- Tissue adhesives based on fibrinogen are used for seamless or seam-supporting connection of human or animal tissue or organ parts, for Wound sealing, hemostasis and promoting wound healing used.
- thrombin converts the (soluble) fibrinogen contained in the ready-to-use, liquid tissue adhesive into (insoluble) fibrin and activates factor XIII, which is also contained, to factor XIIIa. This cross-links the fibrin formed to a high polymer, which is essential for the effectiveness of the tissue adhesive.
- the required thrombin activity can either come from the tissue to be glued (the wound areas) itself or can be added to the tissue glue during the gluing process in the form of a solution containing thrombin and Ca 2+ ions.
- Tissue adhesives based on fibrinogen are already out AT-B-359 653, AT-B-359 652 and AT-B-369 990. she contain fibrinogen and factor XIII and others Proteins such as fibronectin and albumin and optionally Antibiotics.
- Tissue adhesives come in the form of either frozen solutions or as a lyophilisate, since they are not very stable as liquid solutions and not for are durable for a long time. This leads to the fact that the commercial products are either thawed before they are used, i.e. liquefied, or reconstituted from their lyophilisate Need to become. Both measures are not with one insignificant expenditure of time.
- the fibrinogen content is from at least 70 mg / ml of the ready-to-use Tissue adhesive solution and factor XIII content required, taking the ratio of factor XIII to Fibrinogen, expressed in units of factor XIII per Grams of fibrinogen, at least 80.
- Such preparations enable i.a. safe hemostasis, good adhesion of the adhesive to the wound or Fabric surfaces, high resilience of the bonds or Wound seals, a complete absorbability of the Glue in the course of the wound healing process, and she have wound-healing properties.
- the required high fibrinogen content causes that the lyophilized or liquid frozen Fibrinogen preparations only gradually and with increased Temperature - generally only above 25 ° C, mostly above 30 ° C -
- liquid tissue adhesive be reconstituted or liquefied (“melted") can.
- Relatively thin fluid tissue adhesive solutions are particularly advantageous when the tissue adhesive is through thin catheters inserted into the interior of body cavities and to be applied there, or when using the Spray technology, whereby the fabric adhesive is sprayed and used as thin layer is applied to wound surfaces.
- Appropriate Application devices for tissue adhesives are already available Available (EP 0 315 222, EP 0 455 626).
- the solubility of the fibrinogen preparations can change the use of virus inactivation procedures still deteriorate. These are preferably such performed that the lyophilized material one Heat treatment, for example according to EP 0 159 311, is subjected.
- EP-A-0 345 246 a lyophilized fibrinogen preparation which in addition to fibrinogen, at least one biologically compatible Contains surfactant.
- the addition of surfactants causes one improved wetting of the lyophilisate with the Solvent, which causes the rate of dissolution, not but the solubility of the fibrinogen itself - in one given temperature - is improved.
- Such preparations must therefore also at temperatures above 25 ° C, preferably at 37 ° C to be reconstituted.
- EP-A-085 923 describes a lyophilized Fibrinogen preparation, which in addition to fibrinogen Contains substance that a urea or Has guanidine residue.
- Tissue adhesive preparations have a cytotoxic effect on growth inhibit by fibroblasts and to a changed, unphysiological fibrin structure, causing the desired elasticity of the fibrin is lost (cf. Redl et al, Medical World 36, 769-76 (1985).
- With the Inhibition of growth of the fibroblasts i.e. those cells those who initiate the wound healing process go the desired ones wound healing properties of tissue adhesives lost on fibrinogen basis. Due to the lack of elasticity The fibrin produced will also be the required high Resilience of the bonds in vivo questioned.
- the object of the present invention is Storage stable fibrinogen preparations in lyophilized or to provide liquid-frozen form that quickly and easily - preferably without use of additional aids such as heating and / or stirring devices - for ready-to-use fibrinogen or Tissue adhesive solutions reconstituted or liquefied can be, the ready to use Tissue adhesive solutions (with a fibrinogen content of at least 70 mg / ml) already thin enough below 25 ° C are easy to process, and still not the disadvantages of known preparations discussed above, in particular those according to EP-A-085 923.
- the preparations contain, in addition to fibrinogen and, if appropriate, further proteins and auxiliaries and additives, at least one substance which improves the solubility of fibrinogen or lowers its liquefaction temperature and lowers the viscosity of a ready-to-use tissue adhesive solution at room temperature.
- the substance is selected not only according to its effect on the solubility of fibrinogen, but also after the formation of a physiological fibrin structure if the dissolved preparation reacts with an activator and fibrin clots are formed.
- the relevant evidence can be provided after mixing the fibrinogen solution with the same volume of a thrombin-CaCl 2 solution (essentially consisting of 4 IU thrombin and 20 to 40 ⁇ mol CaCl 2 per ml) if the clots formed have a physiological fibrin structure, i.e. the typical, spatially branched structure, as it is formed when thrombin acts on fibrinogen under physiological conditions, ie at an ionic strength of about 0.15 and a pH of about 7.4.
- the physiological structure is characterized by an opaque and tough-elastic clot. SEM images of typical physiological or non-physiological fibrin clots are described, for example, in the publication by Redl et al. Medical World 36, 769-76 (1985).
- the preparation according to the invention is composed in such a way that when used as a tissue adhesive there is no cytotoxic Has an effect, so it is very well tolerated by cells, a good one Enables cell growth and thus an ideal prerequisite for good wound healing. Evidence of this can after diluting the tissue adhesive with the same Volume of a semi-isotonic or isotonic sodium chloride solution are provided if no harmful effects Fibroblasts is detectable.
- a fibrinogen or tissue adhesive solution is in the generally referred to as non-cytotoxic when in Cell overlay test according to Redl et al. (see above) none has a harmful effect on fibroblasts.
- tissue adhesive to a substance that has solubility the preparation improved or their Liquefaction temperature lowers and the viscosity of the ready-to-use tissue adhesive solution at room temperature lowers the other desired biochemical and physical properties of the tissue adhesive practical not be affected.
- the storage-stable fibrinogen preparation according to the invention in liquid-frozen form contains one solubility-improving substance, so that it is in a Temperature from 0 to 25 ° C, preferably below 20 ° C, particularly preferably below 15 ° C, to a solution with a Fibrinogen content of at least 70mg / ml is liquefiable.
- a lower condensing temperature means at the same time a faster liquefaction frozen, concentrated fibrinogen solution if this for example an ambient temperature of 20 ° C - 25 ° C (Room temperature) is exposed. This applies in particular to the frozen preparations according to the invention, which in Ready-to-use, sterile disposable syringes filled and out Sterility double in plastic wrap are welded in.
- the lyophilized fibrinogen or tissue adhesive preparations have the advantage that these at room temperature without special aids (e.g. the combined heating and stirring device according to AT-B-371 719) in acceptable time, i.e. in a period of about one half a minute to 15 minutes, preferably less than 7 Minutes, particularly preferably less than 5 minutes to one Solution with a fibrinogen content of at least 70 mg / ml, can be reconstituted. So far, this was only with Preparations according to EP-A-085 923 the case; however point these preparations, as mentioned above, others serious disadvantages.
- special aids e.g. the combined heating and stirring device according to AT-B-371 719
- preparations according to the invention also allow the particularly quick and easy provision of Fibrinogen solutions for other purposes, for example for Infusion.
- the preparations according to the invention contain one or several of the substances selected from the group of Nucleic bases, nucleosides or nucleotides and Benzoic acid, p-aminobenzoic acid (vitamin H '), p-aminosalicylic acid, hydroxybenzoic acid, hydroxysalicylic acid, Phenylalanine, procaine, niacin, niacinamide, picolinic acid, Vitamin B6 (pyridoxine), hydroxypyridines, Pyridine dicarboxylic acids, pyridine sulfonic acids, Piperidine carboxylic acid esters, pyrimidine, barbituric acid, uracil, Uridine, uridine phosphates, thymine, cytosine, cytidine, Hydroxypyrimidines, thiamine (vitamin B1), morpholine, Pyrrolidone, imidazole, histidine, hydantoin, Pyrazole dicarboxylic
- Fibrinogen preparations are advantageously higher accordingly Ratios of the amount of the substance based on fibrinogen to choose.
- the substance can be in an amount from 0.12-12 mmol, preferably 0.28-5.6 mmol / g fibrinogen, be included.
- the type and amount of the substance should be chosen so that the ready-to-use tissue adhesive preparation is sufficiently fluid at room temperature to be sprayed without any problems, corresponding to a viscosity of less than 400 mm 2 / s (400 cSt.), Preferably less than 300 mm 2 / s (300 cSt). and after mixing the ready-to-use tissue adhesive solution with a thrombin-CaCl 2 solution in a ratio of 1: 1, physiological clots are formed.
- the fibrinogen preparations according to the invention are further characterized by their relatively low salt content, so that the osmolarity of the concentrated tissue adhesive solution is preferably less than 500 mOsm, most preferably less than 400 mOsm. This limitation is necessary to enable the desired good cell compatibility (absence of cytotoxic properties). It was only through the substances according to the invention that it was possible to create lyophilized fibrinogen preparations with a relatively low salt content, which, as described above, can nevertheless be reconstituted without problems at room temperature, relatively thin liquid tissue adhesive solutions (with a fibrinogen content of at least 70 mg / ml), and are well tolerated by cells.
- Preparations known so far are either at Room temperature readily soluble, but damaging to cells (Beriplast®, Biocol®, Bolheal HG-4®) or well cell-compatible, but only at elevated temperature - preferably at 37 ° C - reconstitutable (Tissucol®).
- the preparations according to the invention can be based on their Composition also available as virus-safe preparations to be provided, even in spite of pretreatments Solve inactivation and / or depletion of viruses well.
- Multi-stage treatment methods are particularly effective Heat treatment processes, e.g. Steam treatment at 60 ° C and 80 ° C according to EP-159 311 or combinations of chemical and / or physical treatment methods.
- a heat treatment process is particularly preferred added the solubility-improving substance to the preparation and, if necessary, a nanofiltration before filling in the final container.
- the preparation according to the invention preferably also contains Factor XIII, but also fibronectin and possibly low Amounts of plasminogen, which include for the course of the Wound healing can be beneficial.
- a Preparation according to the invention essentially only Fibrinogen exist, i.e. the only active substance fibrinogen contain.
- tissue adhesive based on fibrinogen and a plasminogen activator inhibitor or plasmin inhibitor, such as aprotinin, ⁇ 2 -plasmin inhibitor, ⁇ 2 -macroglobulin and the like.
- the ready-to-use tissue adhesive solution generally contains 70 to 120 mg fibrinogen, optionally 0.50 to 50 U factor XIII, optionally 0.5 to 15 mg fibronectin, 0 to 150 ⁇ g plasminogen and 0 to 20,000 KIU aprotinin, preferably 1,000 to 15,000 KIU aprotinin per ml.
- a preferred preparation furthermore contains low surfactant concentrations to improve the wettability of the lyophilized preparation or to improve the frozen preparations.
- a virus inactivated (steamed) Tissue adhesive preparation was made according to known methods (see AT-B-369 653, EP 0 345 246) as follows manufactured:
- a plasma cryoprecipitate from pooled human citrate plasma was mixed with a buffer solution (pH 6.5) containing 6.6 g sodium citrate.2H 2 O, 3.4 g NaCl, 10 g glycine, 25,000 KIE aprotinin and 200 IU heparin per 1 at 2 ° C washed and centrifuged.
- the precipitate was adjusted to a protein concentration of 42 g / l with a further buffer solution containing 9.0 g glycine, 1.0 g sodium citrate. 2H 2 O, 25,000 KIE aprotinin and 0.2 g Triton WR 1339.
- Tissue adhesive solutions were used in the following liquefaction test certainly:
- the frozen samples are first in a to 10 ° C incubated for 30 minutes. After that the temperature at intervals of 30 minutes by 2.5 ° C elevated. After each incubation period, the Physical state of the samples by tilting the tubes assessed. The transition from the solid to the liquid state does not occur abruptly, but over a range of several Temperature levels, being gelatinous and viscous Intermediate states are run through.
- This simple test can be used to assess whether a tissue adhesive solution at a given temperature is sufficiently thin to be applied easily to be able to.
- tissue adhesive solutions mentioned after mixing with the same volume of a thrombin-CaCl 2 solution (4 IU thrombin and 40 ⁇ mol CaCl 2 per ml, produced from Thrombin 500, Immuno AG) form physiological, opaque, viscoplastic clots as desired ,
- Example 2 Influence of niacinamide on the viscosity of Tissue adhesive solutions
- Example 4 Influence of niacinamide on the reconstitution time of lyophilized tissue adhesive preparations
- a lyophilized, virus inactivated Tissue adhesive preparation was made up to the heating step prepared analogously to Example 1.
- the material was then dissolved with distilled H 2 O or aqueous niacinamide solutions of different concentrations to a protein concentration of 30 g / l, sterile filtered, filled in 4.0 ml portions into sterile end containers (glass vials) and lyophilized.
- Example 5 Cell Compatibility of According to the Invention tissue adhesives
- tissue adhesive preparations from Example 4 were made after Redl et al., Med. Welt 36, 769-776, 1985, on their Cell compatibility checked. Served as a negative control a well-known cytotoxic tissue adhesive preparation according to EP-A-0 085 923.
- a purified lyophilized fibrinogen preparation (bulk material) was developed essentially according to L.A. Kazal et al, Proc. Soc. Exp. Biol. Med. 113, 989-994, 1963, by glycine precipitation from a human plasma fraction containing fibrinogen manufactured.
- This material was adjusted to a residual moisture of 7 to 8% and heated for further virus inactivation under an N 2 atmosphere at 60 ° C. for 10 hours and then at 80 ° C. for 3 hours.
- the solutions were 50 ml each 125 ml bottles filled and lyophilized.
- the example shows the favorable influence according to the invention solubility-improving substances on the solubility of heated lyophilized fibrinogen preparations that assembled according to infusion preparations and for optimal tolerability after reconstitution about isotonic are.
- a human plasma fraction containing fibrinogen was analyzed with Tween 80 treated, as already essentially in AU-B-18306/92 described to inactivate viruses such as HIV which possibly occur in human plasma.
- the material further purified by precipitation with glycine, as in Example 6 described.
- the precipitate was washed with a 25 mM Sodium citrate solution pH 7.3 washed at 0-2 ° C.
- the purified precipitate became a solution of 50g protein and 10 mmol sodium citrate (pH 7.3) per liter and lyophilized.
- the lyophilized raw material was then placed on a Moisture adjusted from 7-8% and for further Virus inactivation heated. The heating was done under Nitrogen atmosphere over a period of 10 hours at 60 ° C and then for 1 hour at 80 ° C.
- the material was then containing a solution 40 mmol histidine.HCl, 40 mmol niacinamide, 80 mg Tween 80 and 100 000 KIE aprotinin / l to a protein concentration of 40 g / l dissolved and the pH adjusted to pH 7.3 with NaOH.
- Virus-inactivated human albumin (from IMMUNO) was added (6 g / l) and human purified factor XIII, which according to the regulation of A 1548/93 for Virus inactivation was treated (15,000 U / l).
- the solution was sterile filtered and 2.5 ml each in sterile Final container (glass bottles) filled and lyophilized.
- a ready-to-use tissue adhesive solution was obtained, the per ml 90 mg fibrinogen, 2.5 mg fibronectin, 15 mg Albumin, 100 ⁇ mol histidine and 100 ⁇ mol niacinamide contained.
- the average reconstitution time at room temperature was determined as described in Example 4 and was only 4 Minutes.
- This example shows that a combination of solubility-improving substances according to the invention are used, is particularly suitable for the production of readily soluble lyophilized tissue adhesive preparations, which at the same time guarantee a high level of virus security through the two different and described independent measures to inactivate viruses in the course the manufacturing process.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
- Virussicherheit
- hohe Belastbarkeit der Klebungen bzw. Wundversiegelungen, sowie sichere und anhaltende Blutstillung,
- regelbare Haltbarkeit der Klebungen im Körper, durch einen variablen Gehalt an Plasminogen bzw. Fibrinolyseinhibitor,
- vollkommene Resorbierbarkeit des Klebstoffes im Verlaufe des Wundheilungsprozesses,
- wundheilungsfördernde Eigenschaften,
- Gerinnungsreaktion nach Mischen mit einer Thrombinlösung (Gerinnungszeit)
- Vernetzung der Fibrin-γ- und α-Ketten
- Fibrinolyseresistenz
- Reissfestigkeit
- Klebefestigkeit.
Ergebnisse: | |||
zugesetzte Substanz | Gruppe bzw. Verbindung | Konz. mM | Verflüss.- Temp. °C |
kein Zusatz (Vergleich) | - | - | 27,5 |
Benzoesäure (Na-Salz ) | Benzol- | 200 | 15 |
p-Aminobenzoesäure (Na-Salz) | Benzol-, Vitamin | 25 | 20 |
50 | 12,5 | ||
p-Aminosalicylsäure (Na-Salz) | Benzol- | 50 | 15 |
100 | 10 | ||
p-Hydroxybenzoesäur e (Na-Salz) | Benzol- | 50 | 15 |
100 | 10 | ||
Phenylalanin | Benzol- | 100 | 20 |
Procain, HCl | Benzol- | 50 | 15 |
Niacin (Na-Salz) | Pyridin- | 50 | 22,5 |
100 | 10 | ||
Pyridin-, Vitamin | 50 | 12,5 | |
Niacinamid | 100 | 10 | |
200 | <10 | ||
Picolinsäure | Pyridin- | 50 | 22,5 |
100 | 10 - 12,5 | ||
Pyridoxin, HCl Adermin, Vitamin B6 | Pyridin-, Vitamin | 50 | ≤ 10 |
Pyridin-2,6-dicarbonsäure.Na | Pyridin- | 50 | 10 |
2-Hydroxypyridin | Pyridin- | 50 | 15 |
100 | 12,5 | ||
3-Hydroxypyridin | Pyridin- | 200 | 17,5 |
4-Hydroxypyridin | Pyridin- | 50 | 10 |
Pyridin-2,3-dicarbon-säure.Na | Pyridin- | 50 | 17,5 - 20 |
Pyridin-3-sulfonsäure.Na | Pyridin- | 50 | 20 |
100 | 15 | ||
200 | 10 | ||
Pyperidin-4 carbon-säureethylester | Piperidin | 100 | 20 |
Pyrimidin | Pyrimidin- | 50 | 22,5 |
100 | 12,5 | ||
Barbitursäure.Na | Pyrimidin- | 50 | 10 |
Uracil | Pyrimidin-, Nucleinbase | 25 | 22,5 |
Uridin | Pyrimidin-Nucleosid | 50 | 10 |
Uridin-5'-phosphat | Pyrimidin- | 25 | 10 |
Thymin | Pyrimidin-, Nucleinbase | 25 | 22,5 |
Cytosin | Pyrimidin-, Nucleinbase | 25 | 10 |
Cytidin | Pyrimidin-, Nucelotid | 50 | 12,5 |
4-Hydroxypyrimidin (4,3H-Pyrimidon) | Pyrimidin- | 50 | 10 |
Morpholin | Morpholin- | 100 | 15 |
α-Pyrrolidon | Pyrrol- | 50 | 10-12,5 |
100 | 10 | ||
Imidazol | Imidazol- | 100 | 17,5 |
200 | 12,5 | ||
Histidin | Imidazol- | 50 | 20 |
100 | 12,5 | ||
Hydantoin | Imidazol- | 50 | 22,5 |
100 | 10 | ||
Pyrazol-3,5-dicarbonsäure | Pyrazol- | 25 | 12,5 |
Phenazon, Antipyrin | Pyrazol- | 50 | 12,5 |
Adenosin | Purin-, Nucelosid | 25 | 12,5 |
Inosin | Purin-, Nucleosid | 25 | 12,5 |
50 | 10 | ||
Adenosin-5'-phosphat | Purin-, Nucleotid | 6,25 | 22,5 |
12,5 | 10 | ||
Guanosin-5'-phosphat | Purin-, Nucleotid | 6,25 | 15 |
12,5 | 10 | ||
Furan-2-carbonsäure, Brenzschleimsäure | Furan- | 100 | 17,5 |
200 | 10 | ||
Furan-3-carbonsäure | Furan- | 100 | 22,5 |
200 | 12,5 | ||
Ascorbinsäure | Furan-, Vitamin | 50 | 15 |
Xanthosin | Purin-, Nucleosid | 25 | 12,5 |
50 | 10 |
Abhängigkeit der kinematischen Viskosität einer Gewebeklebstofflösung vom Gehalt an Niacinamid bei verschiedenen Temperaturen: | |||||||||
Niacinamid (mM) | Viskosität mm2/s (cSt) bei °C | ||||||||
10,0 | 12,5 | 15,0 | 17,5 | 20,0 | 22,5 | 25,0 | 30,0 | 37,0 | |
0(Vergleich) | 812 | 432 | 238 | 107 | 58,6 | ||||
25 | 1152 | 531 | 294 | 184 | 92,6 | 54,8 | |||
50 | 850 | 471 | 277 | 184 | 132 | 81,3 | 52,9 | ||
100 | 1035 | 556 | 332 | 216 | 152 | 114 | 73,7 | 52,0 | |
200 | 646 | 424 | 286 | 207 | 152 | 118 | 93,5 | 66,2 |
Abhängigkeit der kinematischen Viskosität einer Gewebeklebstofflösung vom Gehalt an Pyridoxin.HCl. | ||||||||
Pyridoxin. HCl (mM) | Viskosität mm2/s (cSt) bei °C | |||||||
12,5 | 15 | 17,5 | 20 | 22,5 | 25 | 30 | 37 | |
0(Vergleich) | 812 | 432 | 238 | 107 | 59 | |||
12,5 | 695 | 372 | 214 | 97 | 57 | |||
25 | 945 | 459 | 252 | 159 | 85 | 51 | ||
50 | 1151 | 583 | 323 | 196 | 147 | 85 | ||
100 | 803 | 499 | 315 | 215 | 153 | 116 | 63 | 47 |
Rekonstitutionszeiten von lyophilisierten Gewebeklebstoffpräparationen in Abhängigkeit vom Gehalt an Niacinamid. | |
Niacinamid, Endkonzentrat (mM) | Rekonstitutionszeit bei RT (Min.) |
0 (Vergleich) | >20 |
50 | 9-11 |
100 | 6-8 |
200 | 4-5 |
Protein | 73,0% (g/g) |
Gerinnbares Protein (Fibrinogen) | 69,4% (g/g) |
Na3-Citrat.2H2O | 19,5% (g/g) |
Zusatz | Niacinamid- Konzentration mmol/l | mmol/g Fibrinogen | Rekonstitutionszeit bei RT (Min.) |
0 (Vergleich) | 0 | 0 | 21 |
Niacinamid | 50 | 2,3 | 13 |
Niacinamid | 100 | 4,5 | 7 |
Claims (14)
- Lagerstabiles Fibrinogenpräparat in lyophilisierter Form oder in flüssig-tiefgefrorener Form zur raschen Bereitung einer gebrauchsfertigen Gewebeklebstofflösung, dadurch gekennzeichnet, dass das Präparat eine die Löslichkeit von Fibrinogen verbessernde Substanz enthält und diese Substanz ausgewählt ist aus Nukleinbasen, Nukleoside oder Nukleotide und Benzoesäure, p-Aminobenzoesäure (Vitamin H'), p-Aminosalicylsäure, Hydroxybenzoesäure, Hydroxysalicylsäure, Phenylalanin, Prokain, Niacin, Niacinamid, Picolinsäure, Vitamin B6 (Pyridoxin), Hydroxypyridinen, Pyridin-dicarbonsäuren, Pyridinsulfonsäuren, Piperidin-carbonsäureester, Pyrimidin, Barbitursäure, Uracil, Uridin, Uridinphosphaten, Thymin, Cytosin, Cytidin, Hydroxypyrimidinen, Thiamin (Vitamin B1), Morpholin, Pyrrolidon, Imidazol, Histidin, Hydantoin, Pyrazol-dicarbonsäuren, Phenazon, Adenosin, Adenosin-Phosphaten, Inosin, Guanosin-Phosphaten, Brenzschleimsäure (Furan-2-carbonsäure), Ascorbinsäure (Vitamin C) und Xantosin."
- Lagerstabiles Fibrinogenpräparat in lyophilisierter Form gemäß Anspruch 1, dadurch gekennzeichnet, dass(i) die Rekonstitutionszeit bei Auflösen mit Wasser bei Raumtemperatur zu einer Lösung mit einem Fibrinogengehalt von mindestens 70 mg/ml bis zu 15 Minuten, vorzugsweise weniger als 7 Minuten beträgt, und(ii) die aus dem Präparat erhaltene gebrauchsfertige Gewebeklebstofflösung nach Mischen mit einer Thrombin-CaCl2-Lösung Fibrinclots mit physiologischer Fibrinstruktur ausbildet.
- Lagerstabiles Fibrinogenpräparat in flüssigtiefgefrorener Form gemäß Anspruch 1, dadurch gekennzeichnet, dass(i) dieses Präparat bei einer Temperatur von 0 bis 25°C, vorzugsweise unter 20°C, zu einer Lösung mit einem Fibrinogengehalt von mindestens 70 mg/ml verflüssigbar ist, und(ii) die aus dem Präparat erhaltene gebrauchsfertige Gewebeklebstofflösung nach Mischen mit einer Thrombin-CaCl2-Lösung Fibrinclots mit physiologischer Fibrinstruktur ausbildet.
- Präparat nach einem der Ansprüche 1 - 3, dadurch gekennzeichnet, dass die genannte Substanz in der gewählten Konzentration im Präparat keine zytotoxische Wirkung hat.
- Präparat nach einem der Ansprüche 1 - 4, dadurch gekennzeichnet, dass die die Löslichkeit von Fibrinogen verbessernde Substanz ausgewählt ist aus der Gruppe der Nukleinbasen, Nukleoside oder Nukleotide.
- Präparat nach einem der Ansprüche 1-4, dadurch gekennzeichnet, dass es sich bei der die Löslichkeit von Fibrinogen verbessernden Substanz um Benzoesäure, p-Aminobenzoesäure (Vitamin H'), p-Aminosalicylsäure, Hydroxybenzoesäure, Hydroxysalicylsäure, Phenylalanin, Prokain, Niacin, Niacinamid, Picolinsäure, Vitamin B6 (Pyridoxin), Hydroxypyridine, Pyridin-dicarbonsäuren, Pyridinsulfonsäuren, Piperidin-carbonsäureester, Pyrimidin, Barbitursäure, Uracil, Uridin, Uridin-Phosphate, Thymin, Cytosin, Cytidin, Hydroxyprimidine, Thiamin (Vitamin B1), Morpholin, Pyrrolidon, Imidazol, Histidin, Hydantoin, Pyrazol-dicarbonsäuren, Phenazon, Adenosin, Adenosin-Phosphate, Inosin, Guanosin-Phosphate, Brenzschleimsäure (Furan-2-carbonsäure), Ascorbinsäure (Vitamin C) und Xantosin handelt.
- Präparat nach einem oder mehreren der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Substanz in einer Menge von 0,03 bis 3 mmol, vorzugsweise von 0,7 bis 1,4 mmol/g Fibrinogen enthalten ist.
- Präparat nach einem oder mehreren der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Gewebeklebstofflösung nach dem Mischen mit dem gleichen Volumen einer Thrombin-CaCl2-Lösung, im wesentlichen bestehend aus 4 I.E. Thrombin und 40 µmol CaCl2 pro ml, nach längstens 10 Minuten bei 37°C einen undurchsichtigen und zähelastischen Fibrinclot ausbilden kann.
- Präparat nach einem oder mehreren der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Gewebeklebstofflösung keine zytotoxische Wirkung hat.
- Präparat nach einem oder mehreren der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass nach Verdünnen der Gewebeklebstofflösung mit dem gleichen Volumen einer isotonen Natriumchloridlösung keine schädigende Wirkung auf Fibroblasten nachweisbar ist
- Gebrauchsfertige Gewebeklebstofflösung, erhältlich durch Rekonstituieren bzw. Verflüssigen des Präparates nach einem oder mehreren der Ansprüche 1 bis 10.
- Lyophilisiertes Fibrinogenpräparat, enthaltend eine die Löslichkeit von Fibrinogen verbessernde Substanz, ausgewählt aus der Gruppe der Nukleinbasen, Nukleoside oder Nukleotide oder der folgenden Gruppe:
Benzoesäure, p-Aminobenzoesäure (Vitamin H'), p-Aminosalicylsäure, Hydroxybenzoesäure, Phenylalanin, Procain, Niacin, Niacinamid, Picolinsäure, Vitamin B6 (Pyridoxin), Hydroxypyridinen, Pyridindicarbonsäuren, Pyridinsulfonsäuren, Piperidin-carbonsäureester, Pyrimidin, Barbitursäure, Uracil, Uridin, Uridin-Phosphaten, Thymin, Cytosin, Cytidin, Hydroxypyrimidinen, Thiamin (Vitamin B1), Morpholin, Pyrrolidon, Imidazol, Histidin, Hydantoin, Pyrazol-dicarbonsäuren, Phenazon, Adenosin, Adenosin-Phosphaten, Inosin, Guanosin-Phosphaten, Brenzschleimsäure (Furan-2-carbonsäure), Ascorbinsäure (Vitamin C) und Xantosin. - Fibrinogenpräparat nach Anspruch 12, dadurch gekennzeichnet, dass die Substanz in einer Menge von 0,12 bis 12 mmol/g Fibrinogen enthalten ist.
- Fibrinogenpräparat nach Anspruch 12, dadurch gekennzeichnet, dass die Substanz in einer Menge von 0,28 bis 5,6 mmol/g Fibrinogen enthalten ist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19617369A DE19617369A1 (de) | 1996-04-30 | 1996-04-30 | Lagerstabile Fibrinogen-Präparate |
DE19617369 | 1996-04-30 |
Publications (4)
Publication Number | Publication Date |
---|---|
EP0804933A2 EP0804933A2 (de) | 1997-11-05 |
EP0804933A3 EP0804933A3 (de) | 2000-03-22 |
EP0804933B1 true EP0804933B1 (de) | 2004-04-07 |
EP0804933B2 EP0804933B2 (de) | 2009-03-11 |
Family
ID=7792949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97106568A Expired - Lifetime EP0804933B2 (de) | 1996-04-30 | 1997-04-21 | Lagerstabile Fibrinogen-Präparate |
Country Status (8)
Country | Link |
---|---|
US (1) | US5962405A (de) |
EP (1) | EP0804933B2 (de) |
JP (1) | JP4094701B2 (de) |
AT (1) | ATE263586T1 (de) |
CA (1) | CA2203961C (de) |
DE (2) | DE19617369A1 (de) |
DK (1) | DK0804933T4 (de) |
ES (1) | ES2218615T5 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT407117B (de) * | 1997-09-19 | 2000-12-27 | Immuno Ag | Fibrinschwamm |
US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
DE19853033A1 (de) * | 1998-11-18 | 2000-05-25 | Centeon Pharma Gmbh | Stabilisierte Proteinzubereitung für einen Gewebekleber |
US6447774B1 (en) | 1998-11-18 | 2002-09-10 | Aventis Behring Gmbh | Stabilized protein preparations for a tissue adhesive |
JP4771594B2 (ja) * | 1999-02-12 | 2011-09-14 | バクスター アクチェンゲゼルシャフト | フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物 |
DE60027695T2 (de) * | 1999-02-12 | 2007-04-26 | Baxter Ag | Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind |
US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
US20030091559A1 (en) * | 2001-10-03 | 2003-05-15 | Woolverton Christopher J. | Storage-stable human fibrinogen solutions |
EP1461053A2 (de) * | 2001-12-04 | 2004-09-29 | Christopher J. Woolverton | Lagerungsbeständiges fibrin-dichtungsmittel |
US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
DE10261126A1 (de) * | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
EP2338442B1 (de) | 2003-12-11 | 2013-01-30 | Isto Technologies Inc. | Teilchenförmiges Knorpelsystem |
US20070014780A1 (en) * | 2005-07-13 | 2007-01-18 | Statseal | Storage-stable human fibrinogen solutions |
CN1911440A (zh) * | 2005-08-08 | 2007-02-14 | 上海莱士血制品有限公司 | 一种用于形成纤维蛋白膜的试剂盒及其应用 |
US8480757B2 (en) | 2005-08-26 | 2013-07-09 | Zimmer, Inc. | Implants and methods for repair, replacement and treatment of disease |
US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
CA2675157A1 (en) * | 2007-01-18 | 2008-07-24 | Baxter International Inc. | Fibrin gel for controlled release of tgf-beta and uses thereof |
WO2008128075A1 (en) | 2007-04-12 | 2008-10-23 | Isto Technologies, Inc. | Compositions and methods for tissue repair |
US8377864B2 (en) | 2007-06-19 | 2013-02-19 | Baxter International Inc. | Fibrin gel for controlled release of PDGF and uses thereof |
US20100028311A1 (en) * | 2008-07-09 | 2010-02-04 | Baxter International Inc. | Using of scaffold comprising fibrin for delivery of stem cells |
AR081227A1 (es) | 2008-12-11 | 2012-07-18 | Baxter Int | Preparaciones basadas en fibrinogenos y polisacaridos sulfatados |
AU2011203927A1 (en) | 2010-01-08 | 2012-07-26 | Baxter Healthcare S.A. | Biomatrices to attract and retain regenerative and reparative cells |
DK2528631T3 (da) | 2010-01-28 | 2014-09-15 | Omrix Biopharmaceuticals Ltd | Fremgangsmåde til forbedret fibrintætning |
ES2951828T3 (es) | 2010-09-23 | 2023-10-25 | Leading Biosciences Inc | Administración de inhibidores de serina proteasa al estómago |
KR101127127B1 (ko) * | 2011-10-27 | 2012-03-21 | 주식회사 녹십자 | 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법 |
CA2861722C (en) | 2011-12-29 | 2020-06-30 | Omrix Biopharmaceuticals Ltd. | Method and device for fast dissolution of solid protein composition |
AU2013232380A1 (en) | 2012-03-12 | 2014-09-25 | The Regents Of The University Of California | Methods and compositions for treating wounds and reducing the risk of incisional hernias |
US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
EP3808338A1 (de) | 2013-09-11 | 2021-04-21 | Eagle Biologics, Inc. | Flüssige proteinformulierungen mit ionischen flüssigkeiten |
KR102397379B1 (ko) | 2014-03-25 | 2022-05-13 | 리딩 바이오사이언시즈, 인크. | 자가소화의 치료용의 조성물 |
AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
CN113908281B (zh) | 2016-01-11 | 2023-09-15 | 恒翼生物医药(上海)股份有限公司 | 用于治疗和预防粘连及肠梗阻的组合物和方法 |
DE102017105256A1 (de) * | 2017-03-13 | 2018-09-13 | Rudolf W. Strümper | Behandlung einer Ruptur eines Körperbestandteils |
KR20240044450A (ko) | 2021-08-13 | 2024-04-04 | 바이오테스트 아게 | 피브리노겐 조성물 및 제조 방법 |
CN118401262A (zh) | 2021-12-30 | 2024-07-26 | 巴克斯特国际公司 | 用于纤维蛋白密封剂的纤维蛋白原和凝血酶溶液以及纤维蛋白密封剂试剂盒 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT359653B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
AT359652B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
AT371719B (de) * | 1980-08-25 | 1983-07-25 | Immuno Ag | Verfahren und vorrichtung zur beschleunigung des aufloesens von schwerloeslichen lyophilisierten arzneimitteln |
AT369990B (de) * | 1981-07-28 | 1983-02-25 | Immuno Ag | Verfahren zur herstellung eines gewebeklebstoffes |
DE3203775A1 (de) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung |
AT389815B (de) * | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
AT379311B (de) * | 1984-03-29 | 1985-12-27 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes |
AT397203B (de) * | 1988-05-31 | 1994-02-25 | Immuno Ag | Gewebeklebstoff |
AT396548B (de) * | 1990-05-03 | 1993-10-25 | Immuno Ag | Biopsieeinrichtung |
AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
US5290918A (en) † | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
US5330974A (en) * | 1993-03-01 | 1994-07-19 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
-
1996
- 1996-04-30 DE DE19617369A patent/DE19617369A1/de not_active Ceased
-
1997
- 1997-04-21 ES ES97106568T patent/ES2218615T5/es not_active Expired - Lifetime
- 1997-04-21 AT AT97106568T patent/ATE263586T1/de active
- 1997-04-21 EP EP97106568A patent/EP0804933B2/de not_active Expired - Lifetime
- 1997-04-21 DK DK97106568T patent/DK0804933T4/da active
- 1997-04-21 DE DE59711487T patent/DE59711487D1/de not_active Expired - Lifetime
- 1997-04-23 US US08/838,975 patent/US5962405A/en not_active Expired - Lifetime
- 1997-04-29 CA CA002203961A patent/CA2203961C/en not_active Expired - Fee Related
- 1997-04-30 JP JP11213797A patent/JP4094701B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DK0804933T3 (da) | 2004-05-17 |
DE59711487D1 (de) | 2004-05-13 |
CA2203961C (en) | 2008-07-08 |
JP4094701B2 (ja) | 2008-06-04 |
EP0804933A3 (de) | 2000-03-22 |
CA2203961A1 (en) | 1997-10-30 |
JPH1036286A (ja) | 1998-02-10 |
ATE263586T1 (de) | 2004-04-15 |
EP0804933B2 (de) | 2009-03-11 |
ES2218615T3 (es) | 2004-11-16 |
US5962405A (en) | 1999-10-05 |
EP0804933A2 (de) | 1997-11-05 |
ES2218615T5 (es) | 2009-07-03 |
DE19617369A1 (de) | 1997-11-06 |
DK0804933T4 (da) | 2009-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0804933B1 (de) | Lagerstabile Fibrinogen-Präparate | |
DE69329795T2 (de) | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator | |
DE3225102C2 (de) | ||
DE60027695T2 (de) | Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind | |
EP0253198B1 (de) | Einkomponenten-Gewebekleber sowie Verfahren zu seiner Herstellung | |
EP0554570B1 (de) | Verfahren zur Herstellung einer stabilen Fibrinogenlösung | |
EP0748633B1 (de) | Gewebeklebstoff auf der Basis von Fibrinogen und Verwendung desselben zur Herstellung eines Hämostyptikum | |
EP1393741A1 (de) | Lagerungsstabile, flüssige Fibrinogen-Formulierung | |
DE69630291T2 (de) | Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält | |
DE3002934A1 (de) | Gewebeklebstoff | |
US20060148698A1 (en) | Storage-stable fibrinogen solutions | |
EP1572229B1 (de) | Stabiles therapeutisches fibrinogen | |
EP0746334B1 (de) | Pharmazeutisches präparat enthaltend plasminogenaktivatoren | |
EP1007109B1 (de) | Gewebekleber auf basis von fibrinogen | |
US20070014780A1 (en) | Storage-stable human fibrinogen solutions | |
US20030091559A1 (en) | Storage-stable human fibrinogen solutions | |
DE69023470T2 (de) | Pasteurisierensverfahren und pasteurisierter kleber zum binden von menschlichen oder tierischen geweben. | |
DE60006248T2 (de) | Verwendung von fibrinogen-multimeren in fibrinklebern | |
DE69719265T2 (de) | Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält | |
DE69724128T2 (de) | Mikropartikel und deren verwendung in der wundbehandlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB IT LI NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAXTER AKTIENGESELLSCHAFT |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 20000516 |
|
17Q | First examination report despatched |
Effective date: 20020118 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB IT LI NL SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 38/36 B Ipc: 7A 61L 26/00 A |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20040407 |
|
REF | Corresponds to: |
Ref document number: 59711487 Country of ref document: DE Date of ref document: 20040513 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: NOVAGRAAF INTERNATIONAL SA |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2218615 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: ZLB BEHRING GMBH Effective date: 20041229 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ZLB BEHRING GMBH |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: RPOT |
|
27A | Patent maintained in amended form |
Effective date: 20090311 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE CH DE DK ES FI FR GB IT LI NL SE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AEN Free format text: AUFRECHTERHALTUNG DES PATENTES IN GEAENDERTER FORM |
|
NLR2 | Nl: decision of opposition |
Effective date: 20090311 |
|
NLR3 | Nl: receipt of modified translations in the netherlands language after an opposition procedure | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T4 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: DC2A Date of ref document: 20090521 Kind code of ref document: T5 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: RPEO |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: BAXTER AKTIENGESELLSCHAFT Free format text: BAXTER AKTIENGESELLSCHAFT#INDUSTRIESTRASSE 67#1221 WIEN (AT) -TRANSFER TO- BAXTER AKTIENGESELLSCHAFT#INDUSTRIESTRASSE 67#1221 WIEN (AT) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20140429 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 59711487 Country of ref document: DE Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE PARTG MB, DE Ref country code: DE Ref legal event code: R081 Ref document number: 59711487 Country of ref document: DE Owner name: BAXTER INTERNATIONAL INC., DEERFIELD, US Free format text: FORMER OWNER: BAXTER AG, WIEN, AT Ref country code: DE Ref legal event code: R081 Ref document number: 59711487 Country of ref document: DE Owner name: BAXTER HEALTHCARE S.A., CH Free format text: FORMER OWNER: BAXTER AG, WIEN, AT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20150427 Year of fee payment: 19 Ref country code: DK Payment date: 20150427 Year of fee payment: 19 Ref country code: SE Payment date: 20150429 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20150427 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: BAXTER INTERNATIONAL INC. Effective date: 20151116 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: BAXTER INTERNATIONAL INC.; US Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT; FORMER OWNER NAME: BAXTER AKTIENGESELLSCHAFT Effective date: 20150917 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150421 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20160426 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20160427 Year of fee payment: 20 Ref country code: GB Payment date: 20160427 Year of fee payment: 20 Ref country code: ES Payment date: 20160426 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20160401 Year of fee payment: 20 Ref country code: FR Payment date: 20160425 Year of fee payment: 20 Ref country code: IT Payment date: 20160421 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20160818 AND 20160824 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: BAXTER INTERNATIONAL INC., CH Free format text: FORMER OWNER: BAXALTA INNOVATIONS GMBH, AT Ref country code: CH Ref legal event code: PFA Owner name: BAXTER TRADING GMBH, AT Free format text: FORMER OWNER: BAXTER EASTERN EUROPE VERTRIEBS GMBH, AT Ref country code: CH Ref legal event code: PFA Owner name: BAXALTA INNOVATIONS GMBH, AT Free format text: FORMER OWNER: BAXTER INNOVATIONS GMBH, AT Ref country code: CH Ref legal event code: PFA Owner name: BAXTER INNOVATIONS GMBH, AT Free format text: FORMER OWNER: BAXTER TRADING GMBH, AT Ref country code: CH Ref legal event code: PFA Owner name: BAXTER EASTERN EUROPE VERTRIEBS GMBH, AT Free format text: FORMER OWNER: BAXTER AKTIENGESELLSCHAFT, AT Ref country code: CH Ref legal event code: NV Representative=s name: KELLER AND PARTNER PATENTANWAELTE AG, CH Ref country code: AT Ref legal event code: HC Ref document number: 263586 Country of ref document: AT Kind code of ref document: T Owner name: BAXALTA INNOVATIONS GMBH, AT Effective date: 20160802 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD Owner name: BAXTER INTERNATIONAL INC., US Effective date: 20160830 Ref country code: FR Ref legal event code: CD Owner name: BAXTER HEALTHCARE SA, CH Effective date: 20160830 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TQ Owner name: BAXTER INTERNATIONAL INC., US Effective date: 20160905 Ref country code: FR Ref legal event code: TQ Owner name: BAXTER HEALTHCARE SA, CH Effective date: 20160905 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 263586 Country of ref document: AT Kind code of ref document: T Owner name: BAXTER INTERNATIONAL INC, US Effective date: 20160913 Ref country code: AT Ref legal event code: PC Ref document number: 263586 Country of ref document: AT Kind code of ref document: T Owner name: BAXTER HEALTHCARE S.A., CH Effective date: 20160913 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20160430 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160422 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 59711487 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20170420 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20170420 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 263586 Country of ref document: AT Kind code of ref document: T Effective date: 20170421 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170420 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20180508 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170422 |